Theraclone: Phase 2a TCN-032 Study Supports Anti-influenza Effect

(RTTNews) - Theraclone Sciences Inc. announced results from a Phase 2a viral challenge study of TCN-032 for the universal treatment of influenza A. While the Phase 2a study did not meet its pre-specified primary endpoint, the overall data support an anti-influenza effect, the company said. In the study, TCN-032 treatment resulted in significant reductions in clinical symptoms score as well as viral load as compared to placebo-treated subjects.

TCN-032 is a recombinant, fully human monoclonal antibody that has the potential to treat patients who are hospitalized with serious influenza, as well as during pandemic outbreaks. The randomized, placebo-controlled, double-blind Phase 2a study was designed to assess the safety and efficacy of TCN-032 in normal human volunteers challenged with influenza A infection.

Theraclone is a biopharmaceutical company focused on the discovery and development of monoclonal antibody therapeutics. On August 1, 2013, Theraclone Sciences and PharmAthene (PIP) announced a definitive merger agreement.